Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.5 USD | +0.16% | +6.24% | +51.22% |
05-03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
05-02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.22% | 2.36B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Kymera Therapeutics : Presents Preclinical Data for Anti-Inflammatory Drug KT-474